Leslie Shaw to Treatment Outcome
This is a "connection" page, showing publications Leslie Shaw has written about Treatment Outcome.
Connection Strength
0.107
-
van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005 Oct 15; 80(2 Suppl):S244-53.
Score: 0.030
-
O'Kane D, Davis L, Ardern-Jones M, Laws P, Shaw L, Cork M, Velangi S, Cooper HL, Hudson R, Smith AB, Rout R. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK. Ulster Med J. 2021 May; 90(2):70-76.
Score: 0.022
-
Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem. 2001 Feb; 34(1):17-22.
Score: 0.021
-
Aguirre FV, Younis LT, Chaitman BR, Ross AM, McMahon RP, Kern MJ, Berger PB, Sopko G, Rogers WJ, Shaw L, et al. Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis. Results from The TIMI II Study. Circulation. 1995 May 15; 91(10):2541-8.
Score: 0.014
-
Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009 Jul; 9(7):1607-19.
Score: 0.009
-
Ardagh MW, Hodgson T, Shaw L, Turner D. Pulse rate over pressure evaluation (ROPE) is useful in the assessment of compensated haemorrhagic shock. Emerg Med (Fremantle). 2001 Mar; 13(1):43-6.
Score: 0.005
-
O'Connor CM, Gattis WA, Shaw L, Cuffe MS, Califf RM. Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol. 2000 Oct 15; 86(8):863-7.
Score: 0.005